Evidence map›Paper›PMID 35350201›Full record

ArticlebioRxiv : the preprint server for biology2022

Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice.

Irene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, Nicholas Lemus, Yonghong Liu, Tsoi Ying Lai, Juan Manuel Carreño, Gagandeep Singh A, Gagandeep Singh B, Michael Schotsaert and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Irene González-DomínguezDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jose Luis MartínezDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Stefan SlamanigDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Nicholas LemusDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Yonghong LiuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Tsoi Ying LaiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Gagandeep Singh ADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Gagandeep Singh BDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ignacio MenaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Stephen McCroskeryDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Lynda CoughlanDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Peter PaleseDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Weina SunDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Icahn School of Medicine at Mount Sinai · USTisch Hospital · USUniversity of Maryland, Baltimore · US

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Experimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3M
Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectorsR21AI157606 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI COUGHLAN, LYNDA · 2020 to 2020
$425k
NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R21 AI157606NIDDK NIH HHS R01 DK130425
6 · The paper itself

Abstract

Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a Newcastle Disease virus (NDV) expressing the prefusion stabilized spike protein from SARS-CoV-2, named NDV-HXP-S. Here, we present the development of next-generation NDV-HXP-S variant vaccines, which express the stabilized spike protein of the Beta, Gamma and Delta variants of concerns (VOC). Combinations of variant vaccines in bivalent, trivalent and tetravalent formulations were tested for immunogenicity and protection in mice. We show that the trivalent preparation, composed of the ancestral Wuhan, Beta and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant.

Identifiers

PMID35350201
PMCPMC8963686
OpenAlexW4220818503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.